Haitian Creole
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)
Neurology: Clinical Practice 2017-Jun

Cerebrovascular fibromuscular dysplasia: The MGH cohort and literature review.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo
Log In / Enskri
Lyen an sove nan clipboard la
Andrea M Harriott
Eli Zimmerman
Aneesh B Singhal
Michael R Jaff
Mark E Lindsay
Guy A Rordorf

Mo kle

Abstrè

BACKGROUND

Fibromuscular dysplasia (FMD) is a rare noninflammatory, nonatherosclerotic arteriopathy of medium-sized arteries affecting up to 7% of the population. The disease can affect any artery but commonly affects renal, extracranial carotid, and vertebral arteries. The epidemiology and natural course of cerebrovascular FMD is unknown and requires further investigation.

METHODS

We present demographic and outcomes data on a case series of 81 patients with cerebrovascular FMD from Massachusetts General Hospital presenting between 2011 and 2015 followed by a review of the peer-reviewed literature.

RESULTS

Patients were a median age of 53 years (±12 SD) and the majority were women. Approximately 50% had a history of tobacco use and more than two-thirds had hypertension. Most patients were on monoplatelet therapy with aspirin; during follow-up, 7 of 67 had progressive disease or additional symptoms. One of 67 patients had a cerebrovascular event: TIA. There were 5 of 67 who had noncerebrovascular events or disease progression and 1 death of unclear cause.

CONCLUSIONS

Cerebrovascular FMD may present with myriad symptoms. Our data support that patients with FMD with symptomatic disease have a low rate of recurrent symptoms or disease progression and can be managed conservatively with stroke risk modification, antiplatelet agents, surveillance imaging, and counseling.

Antre nan paj
facebook nou an

Baz done ki pi konplè remèd fèy medsin te apiye nan syans

  • Travay nan 55 lang
  • Geri èrbal te apiye nan syans
  • Remèd fèy rekonesans pa imaj
  • Kat entèaktif GPS - tag zèb sou kote (vini byento)
  • Li piblikasyon syantifik ki gen rapò ak rechèch ou an
  • Search remèd fèy medsin pa efè yo
  • Izeganize enterè ou yo ak rete kanpe fè dat ak rechèch la nouvèl, esè klinik ak rive

Tape yon sentòm oswa yon maladi epi li sou remèd fèy ki ta ka ede, tape yon zèb ak wè maladi ak sentòm li itilize kont.
* Tout enfòmasyon baze sou rechèch syantifik pibliye

Google Play badgeApp Store badge